We are live on ! Find out more
BIB icon

ProShares Ultra NASDAQ Biotechnology
BIB

Fund managers haven’t disclosed any holdings of BIB yet.

BIB Hedge Fund Activity: Q1 2026 in Review

23 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2026, worth a combined $3.6M — up 70% from $2.12M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIB positions and 2 closed out — a net gain of 4 holders — while 4 added to existing stakes and 3 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $631K. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $64K sold.

  • 23 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2026, up from 19 in Q4 2025.
  • Funds reported $3.6M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2026, up 70% quarter-over-quarter.
  • 6 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2026 and 2 closed out, a net change of +4 holders.
  • The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2026 was Citadel Advisors, an estimated $631K added.
  • The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2026 was Royal Bank of Canada, an estimated $64K sold.

Based on aggregated 13F filings for Q1 2026.